Immediate postoperative measurement of thyroid-stimulating hormone as an early predictor of remission in thyroid-stimulating hormone?secreting pituitary adenomas

被引:6
|
作者
Kim, Soo Heon [1 ]
Ku, Cheol Ryong [2 ,3 ,4 ]
Na, Minkyun [1 ]
Yoo, Jihwan [1 ]
Kim, Woohyun [1 ]
Jung, In-Ho [1 ]
Kim, Kyung Won [2 ]
Moon, Ju Hyung [1 ,3 ,4 ]
Kim, Daham [2 ,3 ,4 ]
Lee, Eun Jig [2 ,3 ,4 ]
Kim, Sun Ho [1 ,5 ]
Kim, Eui Hyun [1 ,3 ,4 ]
机构
[1] Yonsei Univ, Dept Neurosurg, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Dept Internal Med, Div Endocrinol & Metab, Coll Med, Seoul, South Korea
[3] Severance Hosp, Pituitary Tumor Ctr, Seoul, South Korea
[4] Yonsei Univ, Yonsei Endocrine Res Inst, Coll Med, Seoul, South Korea
[5] Ewha Womans Univ, Dept Neurosurg, Coll Med, Seoul, South Korea
关键词
hyperthyroidism; pituitary adenoma; remission; thyroid-stimulating hormone; transsphenoidal surgery; pituitary surgery;
D O I
10.3171/2020.1.JNS192787
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE Thyroid-stimulating hormone (TSH)-secreting pituitary adenoma (TSHoma) is a rare type of pituitary adenoma; thus, little is known about TSHomas. The purpose of this study was to analyze clinical characteristics and therapeutic outcomes of TSHomas based on a single-center experience. The authors also searched for reliable preoperative and early postoperative factors that could predict long-term endocrinological remission. METHODS The clinical, radiological, and pathological characteristics and surgical and endocrinological outcomes of 31 consecutive cases of TSHomas that were surgically treated between 2005 and 2017 were reviewed retrospectively. Preoperative factors were evaluated for their ability to predict long-term remission by comparing remission and non remission groups. TSH and free thyroxine levels were measured at 2, 6, 12, 18, and 24 hours after surgery to determine whether they could predict long-term remission. RESULTS Gross-total removal of tumor was achieved in 28 patients (90.3%), and 26 patients (83.9%) achieved endocrinological remission by surgery alone based on long-term endocrinological follow-up (median 50 months, range 32-81 months). The majority of the tumors were solid (21/31, 67.7%), and en bloc resection was possible in 16 patients (51.6%). Larger tumor size and tumor invasion into cavernous sinus and sphenoid sinus were strong predictors of lower rates of endocrinological remission. Immediate postoperative TSH level at 12 hours after surgery was the strongest predictor, with a 0.62 mu IU/mL cutoff. Postoperative complications included CSF rhinorrhea in one patient and epistaxis in another patient, who underwent additional surgical treatment for the complications. CONCLUSIONS Tumor size and extent are major prognostic factors for both extent of resection and endocrinological remission. The consistency of TSHomas was more likely to be solid, which makes extracapsular dissection more feasible. Long-term remission of TSHomas could be predicted even during the early postoperative period. https://thejns.org/doi/abs/10.3171/2020.1.JNS192787
引用
收藏
页码:794 / 800
页数:7
相关论文
共 50 条
  • [1] Thyroid-stimulating hormone pituitary adenomas
    Clarke, Michelle J.
    Erickson, Dana
    Castro, M. Regina
    Atkinson, John L. D.
    JOURNAL OF NEUROSURGERY, 2008, 109 (01) : 17 - 22
  • [2] Perianesthetic Management of Patients With Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas
    Dyer, Matthew W.
    Gnagey, Amy
    Jones, Bryan T.
    Pula, Roger D.
    Lanier, William L.
    Atkinson, John L. D.
    Pasternak, Jeffrey J.
    JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY, 2017, 29 (03) : 341 - 346
  • [3] Thyroid-stimulating hormone-secreting ectopic pituitary adenoma of the nasopharynx
    Nishiike, Suetaka
    Tatsumi, Ke-ita
    Shikina, Takashi
    Masumura, Chisako
    Inohara, Hidenori
    AURIS NASUS LARYNX, 2014, 41 (06) : 586 - 588
  • [4] Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas : Single Institutional Experience of 14 Consecutive Cases
    Byun, Joonho
    Kim, Jeong Hoon
    Kim, Young-Hoon
    Cho, Young Hyun
    Hong, Seok Ho
    Kim, Chang Jin
    JOURNAL OF KOREAN NEUROSURGICAL SOCIETY, 2020, 63 (04) : 495 - 503
  • [5] Thyroid-stimulating hormone: pitfalls in the measurement and interpretation
    Koehler V.F.
    MMW - Fortschritte der Medizin, 2024, 166 (5) : 62 - 65
  • [6] Coexistence of Thyroid-Stimulating Hormone-Secreting Pituitary Adenoma and Graves' Hyperthyroidism
    Kamoun, Mahdi
    d'Herbomez, Michele
    Lemaire, Christine
    Fayard, Armelle
    Desailloud, Rachel
    Huglo, Damien
    Wemeau, Jean-Louis
    EUROPEAN THYROID JOURNAL, 2014, 3 (01) : 60 - 64
  • [7] Samples spiked with pituitary-derived thyroid-stimulating hormone may disguise the extent of differences between thyroid-stimulating hormone assays
    Kalaria, Tejas
    Fenn, Jonathan
    Sharrod-Cole, Hayley
    Sanders, Anna
    Ford, Clare
    Gama, Rousseau
    ANNALS OF CLINICAL BIOCHEMISTRY, 2021, 58 (06) : 638 - 645
  • [8] Chemiluminescent immunoassay for thyroid-stimulating hormone
    Yin, DG
    He, YF
    Liu, YB
    Shen, DC
    Han, SQ
    Guan, GY
    Luo, ZF
    Zhong, RG
    CHINESE JOURNAL OF ANALYTICAL CHEMISTRY, 2004, 32 (07) : 893 - 896
  • [9] Thyroid-Stimulating Hormone and Clinical Outcomes
    Perez, Ana Cristina
    Jhund, Pardeep S.
    Stott, David J.
    Gullestad, Lars
    Cleland, John G. F.
    van Veldhuisen, Dirk J.
    Wikstrand, John
    Kjekshus, John
    McMurray, John J. V.
    JACC-HEART FAILURE, 2014, 2 (01) : 35 - 40
  • [10] Recombinant thyroid-stimulating hormone in differentiated thyroid cancer
    Krausz, Y
    Uziely, B
    Nesher, R
    Chisin, R
    Glaser, B
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2001, 3 (11): : 843 - +